야마토게임 다운로드 44.rsk396.top 바로가기 황금성게임앱

바다이야기 도박바다이야기릴게임바다이야기예시종료릴게임환수율

야마토게임 다운로드 56.rsk396.top 황금성게임앱

야마토게임 다운로드 48.rsk396.top 황금성게임앱

야마토게임 다운로드 54.rsk396.top 황금성게임앱

야마토게임 다운로드 12.rsk396.top 황금성게임앱

야마토게임 다운로드 13.rsk396.top 황금성게임앱

야마토게임 다운로드 83.rsk396.top 황금성게임앱

야마토게임 다운로드 55.rsk396.top 황금성게임앱

야마토게임 다운로드 4.rsk396.top 황금성게임앱

야마토게임 다운로드 47.rsk396.top 황금성게임앱

야마토게임 다운로드 37.rsk396.top 황금성게임앱

바로가기 go !! 바로가기 go !!

게임몰릴게임 바다이야기 고래 출현 슬롯게시판 바다이야기파칭코 야마토게임기 황금성 릴게임 바다이야기 예시 무료충전게임 다빈치 릴게임 먹튀 강원랜드이기는법 슬롯머신 바다이야기 게임 방법 릴황 금성 바다이야기 릴게임 바다이야기 무료체험 바다이야기게임다운 바다이야기백경 슬롯머신 잭팟 야마토게임공략방법 파라 다이스 오션 슬롯머신 원리 알라딘 프라그마틱 슬롯 추천 다빈치 릴게임 먹튀 야마토게임하기 오리지널바다이야기 알라딘예시 릴황금성 모바일파칭코 백경릴게임 온라인빠찡고 바다이야기황금고래 무료 슬롯 메타 바다이야기2화 황금성연타 게임몰 릴게임 인터넷 바다이야기 릴게임주소 손오공 게임 바다신2게임 온라인신천지 신천지무료 오리지날바다 무료황금성게임 신천지게임랜드 바다이야기게임다운로드 슬롯사이트 슬롯머신게임 오션파라 다이스게임다운로드 야마토2 릴게임 강원랜드 슬롯머신 추천 바다이야기 시즌7 pc빠찡꼬게임 바다이야기apk 릴게임손오공 오션파라다이스 예시 오션파라다이스3 슬롯 추천 디시 잭팟게임 온라인 슬롯 게임 추천 창원경륜경륜장 카카오릴게임 릴짱 슬롯머신 하는법 바다이야기 환전 황금성3게임다운로드 무료슬롯 바다이야기게임다운 바다이야기 먹튀사이트 바다이야기 무료머니 황금성게임다운로드 10원야 마토 바다신2다운로드 황금성사이트 야마토게임무료다운받기 야마토게임다운로드 강원랜드 슬롯머신 가격 파칭코슬롯 무료릴게임 바다이야기하는법 카지노 슬롯머신 규칙 바다이야기상어 야마토게임기 릴게임종류 오리지널황금성 프라그마틱무료메타2 황금성pc버전 황금성 무료머니 야마토게임장 야마토게임후기 우주전함야마토먹튀 바다이야기2화 백경게임 다운로드 바다이야기주소 슬롯 무료 사이트 다빈치게임 바둑이라이브 무료백경 오션파라다이스시즌7 스톰게임 일본 파칭코 인터넷백경 바다이야기환전 신천지게임 하는곳 야마토2 온라인 런처 프라그마틱 슬롯 조작 바다이야기기프트전환 로드할 오락실슬롯머신 신천지다운로드 야마토2릴게임 인터넷 바다이야기 릴게임황금포카성 양귀비게임 하이로우하는법 꽁머니릴게임 모바일야마토 인터넷야마토릴게임 프라그마틱 슬롯 하는법 릴게임다빈치 황금성후기 바다이야기apk 야마토5게임 기 알라딘게임잭팟 야마토게임장 This article was released as Pharm Edaily Premium Content on July 3, 2025, at 9:00 AM.


[NA Eun-kyung, Edaily Reporter] On July 2, biotech and healthcare stocks moved quietly overall with no stocks hitting limit-up or limit-down thresholds. But investor sentiment diverged around upcoming FDA-related events. Shares of Medipost declined amid market concerns over poten한국유리 주식
tial fundraising ahead of a critical U.S. clinical trial. In contrast, CorestemChemOn, which had faced scrutiny for a failed Phase 3 trial, rebounded after regaining its certification as an innovativepc게임
pharmaceutical company. Meanwhile, Intron Biotechnology surged double digits following positive U.S. patent developments that boosted expectations for future license-out opportunities.
Medi온라인 릴게임
post Falls on Funding Concerns Ahead of U.S. Phase 3 Trial
Medipost shares dropped 9.8% to 11,950 won after reports emerged that the company was preparing to raise around 100 billion won thr증권수수료면제
ough a rights offering.



Medipost ‘CARTISTEM’ (Source: Medipost)


The stem cell biotech, founded in 2000 by former Samsung화장품관련주
Medical Center professor Yoon Sun Yang, is currently conducting Phase 3 trials of its lead osteoarthritis treatment Cartistem in Japan and the United States. The Japan trial is nearing completion, while the U.S. trial is slated to submit its IND application by year-end.
Market observers believe the stock slump reflects concerns over the high costs of the U.S. trial, especially as reports surfaced that the company had begun distributing teaser letters to potential investors.
A Medipost official said, “We are reviewing investment options to secure sufficient cash ahead of clinical trials in the U.S. and Japan, but the amount and timing have not been finalized.”
Cartistem was the second stem cell therapy approved in Korea back in 2012. The product gained public attention when former national football coach Guus Hiddink underwent bilateral knee surgery using Cartistem in 2014 and 2022. More recently, Medipost hosted a “Train-the-Trainer” program in Korea for renowned U.S. team physicians specializing in cartilage regeneration from the NBA and MLB to observe Cartistem procedures firsthand.
CorestemChemOn Rebounds Ahead of FDA Meeting
CorestemChemOn shares rose nearly 16% intraday to 3,090 won after the company announced it had regained its status as an Innovative Pharmaceutical Company, a government designation offering various regulatory and financial benefits?such as R&D grant scoring boosts, tax and pricing incentives, access to policy funding, and relaxed facility requirements.
The re-certification is rare for previously designated firms and comes as a welcome development after a tough year. In 2023, CorestemChemOn’s ALS therapy Neuronata-R failed to meet its primary endpoint in a Phase 3 trial conducted under the oversight of both the Korean MFDS and the U.S. FDA, sending its shares into a steep decline. The failed trial had raised concerns about potential difficulties in securing out-licensing deals and future funding.
The company now sees the re-certification as a credibility boost. “The designation will help us offset unexpected risks over the next three years,” a company official said.
CorestemChemOn is also adjusting its regulatory strategy. In April, it filed a supplemental application with the MFDS, targeting slow progressor ALS patients using subgroup data on ALSFRS-R scores, composite survival indices (CAFS), and forced vital capacity (SVC). The company expects a response requesting data clarification soon.
In the U.S., CorestemChemOn is preparing for an FDA Type C meeting slated for October. “We’re preparing up to 10 key questions in coordination with our CRO and analyzing our data,” the official said. “We are referencing Biogen’s Tofersen, which received accelerated FDA approval based on biomarker-driven evidence similar to what Neuronata-R has shown.”
Intron Biotechnology Surges on Patent Filing for Key Pipeline
Intron Biotechnology soared 16.1% to close at 4,285 won after announcing that it had filed a U.S. patent for three modified endolysin-based drug candidates showing strong antimicrobial activity against gram-negative and super bacteria.
The compounds―PKL200, TSL2200, and EAL2200―were derived from its ‘itLysin’ platform under the GN200 development program. According to the company, itLysin enhances permeability through the outer membrane of gram-negative bacteria, a longstanding barrier that traditional antibiotics often fail to overcome.
“Infections caused by gram-negative pathogens are on the rise globally, yet conventional antibiotics struggle to penetrate the outer membrane,” the company said. “Our candidates are engineered to overcome that limitation.”
Vice President Sang-Hyun Kang of Intron Bio’s Biotechnology Research Center emphasized the commercial strategy behind the filing. “Unlike previous approaches that prioritized filing early, this was a calculated move after thorough business preparation,” he said. “This secures both IP rights and technology confidentiality.”
Despite recent setbacks including a second license revocation of its core asset SAL200 Intron remains focused on improving SAL200’s production yield in hopes of reviving out-licensing potential.
Let me know if you‘d like this formatted into a press release or included with stock price charts.
나은경 (eeee@edaily.co.kr)